Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma - Trial NCT05983237
Access comprehensive clinical trial information for NCT05983237 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Peking University Cancer Hospital & Institute and is currently Not yet recruiting. The study focuses on Melanoma. Target enrollment is 50 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Peking University Cancer Hospital & Institute
Timeline & Enrollment
Phase 1/2
Aug 31, 2023
Dec 31, 2025
Primary Outcome
Objective Response Rate (ORR)
Summary
The purpose of this study is to evaluate how well fuzoparib in combination with camrelizumab
 and temozolomide works in treating patients with advanced, metastatic melanoma with the
 homologous recombination (HR) pathway gene mutation / alteration.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05983237
Non-Device Trial